Shenzhen Salubris Pharmaceuticals (002294) Q3 2025 earnings summary

Executive summary

• Achieved revenue of ¥1.11 billion in Q3 2025, up 15.85% year-over-year; net profit attributable to shareholders was ¥215.63 million, up 30.19% year-over-year.

• New product sales accelerated, becoming the main growth driver; focus remains on cardiovascular and CKM chronic disease fields.

• R&D pipeline expanded to 74 projects, with over 50 focused on CKM chronic diseases; several core products in late-stage clinical trials.

Financial highlights

• Q3 2025 revenue: ¥1.11 billion (+15.85% YoY); YTD revenue: ¥3.24 billion (+8.00% YoY).

• Q3 net profit attributable to shareholders: ¥215.63 million (+30.19% YoY); YTD: ¥580.71 million (+13.93% YoY).

• Q3 basic/diluted EPS: ¥0.19 (+26.67% YoY); YTD: ¥0.52 (+13.04% YoY).

• Operating cash flow for Q3: ¥776.45 million (-9.07% YoY).

• Total assets at period end: ¥10.98 billion (+4.95% from year-end 2024).

Outlook and guidance

• New products expected to continue driving growth; digital chronic disease management platform under development to enhance patient lifecycle management.

• Several innovative drugs in late-stage clinical trials, with anticipated launches in the coming years.